The U.S. Food and Drug Administration on Tuesday issued modified risk tobacco product (MRTP) orders covering 20 Zyn nicotine pouch products, the agency confirmed in announcements distributed through company channels and Business Wire on June 30, 2026. It is the first time the FDA has cleared a nicotine pouch to be marketed with reduced-risk language, and the largest single MRTP action in the agency’s 17-year tobacco oversight history.
Zyn is owned by Swedish Match, the Swedish smokeless tobacco company acquired by Philip Morris International (PM) in November 2022 for $16 billion. The authorization is the regulatory keystone for PM’s smoke-free pivot — the company has staked its long-term valuation on shifting revenue away from combustibles, and Zyn is the fastest-growing piece of that mix.
PM shares traded at $181.78 around midday, down 0.60% on the session, after running up ahead of the decision. The stock is still up 15.3% year-to-date, outperforming the S&P 500’s 9.5% gain.
How rare an MRTP order actually is
The FDA gained authority to clear modified risk claims under the 2009 Family Smoking Prevention and Tobacco Control Act. In the 17 years since, only four product families had ever received MRTP orders. Zyn is the fifth.
| Product | Company | Category | FDA Order | Date |
|---|---|---|---|---|
| General Snus (8 SKUs) | Swedish Match | Smokeless | Risk modification | Oct 2019 |
| IQOS Heating System | Philip Morris | Heat-not-burn | Exposure modification | Jul 2020 |
| VLN King & Menthol King | 22nd Century Group | Cigarettes | Exposure modification | Dec 2021 |
| Copenhagen Classic Snuff | U.S. Smokeless Tobacco | Smokeless | Risk modification | Mar 2023 |
| Zyn (20 SKUs) | Swedish Match (PM) | Nicotine pouch | Modified risk | Jun 30, 2026 |
MRTP orders come in two flavors. An exposure modification order lets a company say its product reduces or eliminates a harmful substance — that is what IQOS received. A risk modification order is stronger: it allows claims that switching to the product reduces the risk of disease relative to cigarettes. Zyn received the higher bar, matching what General Snus and Copenhagen Classic obtained.
Why the stock did not pop
PM did not rally on what is unambiguously a regulatory win because the market had largely positioned for it. Swedish Match opened its MRTP application in June 2025, and PM management telegraphed confidence through the 2026 first-quarter earnings call, citing the FDA’s constructive feedback during the science review. The stock advanced from $159 to $192 between January and June 2026 on those signals, a 21% move in six months.
The down-tick on the news fits a textbook buy-the-rumor pattern, not a rejection. Morgan Stanley reiterated an Overweight rating with a $200 price target ahead of the decision, and the average analyst price target sits at $193.86 according to consensus data.
Zyn is no longer a small line item
Zyn launched in the United States in 2014 and Swedish Match built it into a market leader well before PM took control. The volume curve is the story:
Zyn’s US share of the nicotine pouch category was around 60% as of 2022 and crossed 70% in 2023, per industry tracking cited in PM’s investor disclosures. That dominance is what makes the MRTP designation commercially relevant: the brand now has the regulatory cover to remind consumers in advertising that switching from cigarettes to Zyn is, in the FDA’s view, less harmful.
Reading the competitive shock
British American Tobacco (BTI) and Altria (MO) sit on the other side of the trade. BTI’s Velo pouch and Altria’s On! brand are the two closest competitors, and neither holds an MRTP order. Each company has its own application in process, but the FDA does not run on a fixed schedule, and the science-review process for IQOS took roughly three years from submission to authorization.
In the near term, Zyn now gets a marketing advantage that competing pouches cannot copy at retail. Consumer products go-to-market is heavily about shelf placement and category-defining language, both of which the MRTP order strengthens.
What changes commercially
The order does not change the product. Zyn cans, mint and citrus flavors, and the 3-mg and 6-mg strengths sold today remain the same. What changes is the language Philip Morris can put on advertising, packaging, and point-of-sale materials. The FDA-authorized claim will reference reduced exposure to cigarette-related harm in adults who completely switch from combustible cigarettes — close to the language IQOS received in 2020.
The authorization also brings tighter post-market obligations. The FDA requires sponsors of MRTP-cleared products to submit ongoing data on consumer perception, youth uptake, and switching behavior. Failing those reviews can result in the order being withdrawn, as Swedish Match learned with parts of the General Snus order that lapsed in 2023.
The bigger picture
PM’s leadership has been explicit that smoke-free products are the future of the business, and the 2022 Swedish Match deal was the largest single bet on that thesis. Smoke-free revenue accounted for roughly 39% of PM’s net revenues as of 2024 annual results, with the company targeting more than half by 2030.
The Zyn MRTP order does not move that ratio overnight. But it removes a regulatory uncertainty that has hung over the smoke-free thesis since the Swedish Match acquisition closed, and it confirms the FDA’s willingness to differentiate nicotine pouches from combustible tobacco at the policy level.
Sources
- FDA Center for Tobacco Products — Modified Risk Tobacco Products
- FDA — Family Smoking Prevention and Tobacco Control Act overview
- Philip Morris International Investor Relations
- Yahoo Finance — Philip Morris (PM) quote and news
- SEC EDGAR — Philip Morris International 10-K filings
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.